Supplementary Table 1 Effects on week 144 suppression (VL <80 copies/ml) of pre-ART VL, sdNVP, age at ART initiation and ART-strategy randomisation – interaction model

<table>
<thead>
<tr>
<th>Interaction model</th>
<th>OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-ART VL (per log_{10} higher)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sdNVP</td>
<td>0.21 [0.07-0.61]</td>
<td>0.004</td>
</tr>
<tr>
<td>No sdNVP</td>
<td>0.70 [0.46-1.04]</td>
<td>0.08</td>
</tr>
<tr>
<td>Heterogeneity</td>
<td>0.04</td>
<td></td>
</tr>
<tr>
<td>sdNVP exposure at VL=6 log_{10} (yes vs no)</td>
<td>1.92 [0.95-3.87]</td>
<td>0.07</td>
</tr>
<tr>
<td>Age at ART initiation (per year younger)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2NRTI+NNRTI (Arms A and B)</td>
<td>0.47 [0.28-0.78]</td>
<td>0.004</td>
</tr>
<tr>
<td>3NRTI (Arm-C)</td>
<td>1.23 [0.70-2.14]</td>
<td>0.47</td>
</tr>
<tr>
<td>Heterogeneity</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>3NRTI vs 2NRTI+NNRTI aged 1 year</td>
<td>1.23 [0.62-2.46]</td>
<td>0.55</td>
</tr>
</tbody>
</table>

Effect from adding additional variables in main model (Table 2) into this interaction model similar to in main model (data not shown).
Supplementary Figure 1: Patient disposition

All ARROW children (n=1206)

Aged 3–<36 months (n=370)

Initiated efavirenz-based ART*(n=3) Not analysed

Initiated nevirapine-based ART: lamivudine+abacavir+nevirapine with (Arms B & C) or without (Arm A) zidovudine (n=367)

Previous sdNVP (n=78) Exposure No previous sdNVP (n=289)

Week 36
Arm A: continue lamivudine+abacavir+nevirapine
Arm B: lamivudine+abacavir+nevirapine (drop zidovudine)
Arm C: lamivudine+abacavir+zidovudine (drop nevirapine)

Alive and in follow-up (n=74)
Excluded: died† (n=3)
Excluded: lost to follow-up** (n=1)
VL measurement available (n=73)
VL and covariates available*** (n=71)

Alive and in follow-up (n=276)
Excluded: died† (n=11)
Excluded: lost to follow-up** (n=2)
VL measurement available (n=272)
VL and covariates available*** (n=271)

Week 48

Alive and in follow-up (n=73)
Excluded: lost to follow-up†† (n=1)
VL measurement available (n=73)
VL and covariates available*** (n=71)

Week 144

Alive and in follow-up (n=273)
Excluded: lost to follow-up‡‡ (n=3)
VL measurement available (n=272)
VL and covariates available*** (n=272)

* Aged 32, 35, 35 months
** All lost to follow-up <24 weeks
*** For the remaining children, pre-ART VL was not available
† 2 died <24 weeks; latest VL in the other child was 586 copies/ml
†† Latest VL 327742 copies/ml
‡ 6 died <24 weeks; latest VLs in the remainder were <80 (n=1), 148 (n=1) and ≥10000 (n=3) copies/ml
‡‡ Latest VL <80 (n=2) and 186038 copies/ml (n=1)